Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

News Conference News TCT 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Yael L. Maxwell

November 05, 2024

News Conference News TCT 2024

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

Caitlin E. Cox

October 31, 2024

Presentation TCT 2024

3-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of the Biodegradable Polymer Firehawk Sirolimus-Eluting Coronary Stent: Primary Outcomes of the TARGET DAPT Trial

Presenter: Hongbo Yang

October 30, 2024

More Registry Data Show Post-TAVI Benefits With Sentinel but No Stroke Impact

News Conference News TCT 2024

LAAO Outcomes Similar Regardless of Operator’s Specialty

Todd Neale

October 27, 2024

Presentation TCT 2024

TCT 289: Different Efficacy of 12-Month Dual Antiplatelet Therapy Following Off-Pump Versus On-Pump Coronary Artery Bypass Grafting

Presenter: Woo Jin Jang

October 27, 2024

Presentation TCT 2024

TCT 401: Impact of >12-Month Versus =12-Month Dual Antiplatelet Therapy on Long-Term Outcomes After Chronic Total Occlusion Percutaneous Coronary Intervention

Presenter: Yao Jiang

October 27, 2024

Presentation TCT 2024

TCT 286: Impact of Dual Antiplatelet Therapy on Secondary Revascularization due to Native Vessel Disease Progression v/s Graft Failure After Coronary Artery Bypass Graft

Presenter: IFTIKHAR CH

October 27, 2024

Advertisement

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

3-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of the Biodegradable Polymer Firehawk Sirolimus-Eluting Coronary Stent: Primary Outcomes of the TARGET DAPT Trial

More Registry Data Show Post-TAVI Benefits With Sentinel but No Stroke Impact

LAAO Outcomes Similar Regardless of Operator’s Specialty

TCT 289: Different Efficacy of 12-Month Dual Antiplatelet Therapy Following Off-Pump Versus On-Pump Coronary Artery Bypass Grafting

TCT 401: Impact of >12-Month Versus =12-Month Dual Antiplatelet Therapy on Long-Term Outcomes After Chronic Total Occlusion Percutaneous Coronary Intervention

TCT 286: Impact of Dual Antiplatelet Therapy on Secondary Revascularization due to Native Vessel Disease Progression v/s Graft Failure After Coronary Artery Bypass Graft

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content